Shukla Sanjay 4
4 · aTYR PHARMA INC · Filed Feb 6, 2023
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
Shukla Sanjay
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common stock
2023-02-03+10,375→ 61,173 total - Exercise/Conversion
Restricted Stock Unit
2023-02-03−10,375→ 31,125 total→ Common Stock (10,375 underlying)
Footnotes (3)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.